Lisdexamfetamine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Lisdexamfetamine

Examples of brand names: Elvanse [DE]

ATC code: N06BA12

Main use (for orientation): ADHD

Documented research summary

Illicit amphetamine or previously discontinued lisdexamfetamine in cases does not establish causal cannabinoid–lisdexamfetamine evidence. Missing data do not establish safety.

Uncertainties and limitations

The 28 cannabinoid names in the register define the search scope, not 28 clinically studied pairs. Missing data do not establish safety.

No complete new systematic literature search and no independent medical or pharmaceutical professional approval. Note the dosage form and the country of authorisation of the product information.

Strictly distinguish prodrug activation from the active substance.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names within the documented search scope; no newly established direct finding for the target cannabinoid–drug pair. This must not be equated with 28 clinically studied combinations.

Evidence status: Drug properties from regulatory product information; insufficient data for a direct cannabinoid–drug pair finding in the material assessed.

Mechanism / drug context: Activation in erythrocytes, not by CYP; CYP2D6 contributes to further amphetamine breakdown.

Type of supporting material: Targeted product-information review and documented individual literature screening; no newly verified direct cannabinoid–drug pair study.

Clinical interpretation: The clinical relevance of a specific cannabinoid combination has not been determined. Drug context may warrant individual professional review, but neither a blanket warning level nor an assurance of safety.

Context: Strictly distinguish prodrug activation from the active substance.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [VF_L_D0427]: Medicine information: properties of the active substance

Statement supported: Activation in erythrocytes, not by CYP; CYP2D6 contributes to further amphetamine breakdown. Product information: drug context, not evidence for a specific cannabinoid pair or proof of safety.

Source: LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE) CAPSULE [AMNEAL PHARMACEUTICALS LLC] [VF_L_D0427]

Source role [VF_P_34200122]: Screened search result: no established pair evidence

Statement supported: Multifactorial case involving amphetamine/cannabis use and prescribed lisdexamfetamine; no isolated causal evidence for the target pair.

Source: Acute Myocardial Injury in a Patient with Attention Deficit Hyperactivity Disorder and History of Substance Abuse: A Multimodality Imaging Point of View. [VF_P_34200122]

Source role [VF_P_42137660]: Screened search result: no established pair evidence

Statement supported: Multi-ingredient supplement case; lisdexamfetamine reportedly discontinued 1.5 weeks earlier. No verified causal cannabinoid–lisdexamfetamine interaction.

Source: A Case of Manic-Like Symptoms and Confusion After Supplement Ingestion. [VF_P_42137660]

Source role [C_PROTOCOL_D0427]: Documented search result

Statement supported: Documented title/abstract search scope for the active substance. The link displays the reproducible search query, not a study or proof that no interaction exists. Search date: 23 October 2026. Further search runs are documented in the research dataset.

Source: Reproducible literature search strategy: Lisdexamfetamin [C_PROTOCOL_D0427]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The existing individual review, label review and literature screening were read in full; targeted original PK/interaction passages were checked again, but not all product information and search results were newly reviewed in full text. Search findings are limited to the documented V5 search runs. The linked excluded search result was rechecked using its archived abstract or correction metadata record; this does not imply complete new access to the full text.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[VF_L_D0427] LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE) CAPSULE [AMNEAL PHARMACEUTICALS LLC]

Original source / bibliographic reference

Authors: Marketing authorisation holder; official product information via DailyMed

Year: 2026

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_34200122] Acute Myocardial Injury in a Patient with Attention Deficit Hyperactivity Disorder and History of Substance Abuse: A Multimodality Imaging Point of View.

Original source / bibliographic reference

Authors: Saeed S, Rotevatn S, Schjøtt J, Larsen TH.

Year: 2021

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.3390/jcdd8060067

PMID: 34200122

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[VF_P_42137660] A Case of Manic-Like Symptoms and Confusion After Supplement Ingestion.

Original source / bibliographic reference

Authors: Shah P, Ehrman S, Reed R.

Year: 2026

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.7759/cureus.106949

PMID: 42137660

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[C_PROTOCOL_D0427] Reproducible literature search strategy: Lisdexamfetamin

Original source / bibliographic reference

Authors: Europe PMC; documented search run

Year: 2026

Source type: Search strategy / screening protocol – not an individual study

Source access – 23 October 2026: Research protocol with machine-readable search results – not an individual study.

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility